Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Hepatopulmonary Syndrome
NCT02021929Phase 2Terminated
- Sponsor
- University of Pennsylvania
- Start
- Mar 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in hepatopulmonary syndrome (HPS), sponsored by University of Pennsylvania. Started Mar 2014; status: terminated.
02
Drugs
sorafenib
03
Conditions
hepatopulmonary syndrome (HPS)
Beyond the preview
Go deeper on NCT02021929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02021929.